CN110664785B - 一种山楂黄酮微胶囊及其制备方法和应用 - Google Patents
一种山楂黄酮微胶囊及其制备方法和应用 Download PDFInfo
- Publication number
- CN110664785B CN110664785B CN201911013909.XA CN201911013909A CN110664785B CN 110664785 B CN110664785 B CN 110664785B CN 201911013909 A CN201911013909 A CN 201911013909A CN 110664785 B CN110664785 B CN 110664785B
- Authority
- CN
- China
- Prior art keywords
- solution
- hawthorn flavone
- gelatin
- hawthorn
- flavone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 title claims abstract description 141
- 229930003944 flavone Natural products 0.000 title claims abstract description 141
- 235000011949 flavones Nutrition 0.000 title claims abstract description 141
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 title claims abstract description 141
- 150000002212 flavone derivatives Chemical class 0.000 title claims abstract description 140
- 235000009917 Crataegus X brevipes Nutrition 0.000 title claims abstract description 112
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 title claims abstract description 112
- 235000009685 Crataegus X maligna Nutrition 0.000 title claims abstract description 112
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 title claims abstract description 112
- 235000009486 Crataegus bullatus Nutrition 0.000 title claims abstract description 112
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 title claims abstract description 112
- 235000009682 Crataegus limnophila Nutrition 0.000 title claims abstract description 112
- 235000004423 Crataegus monogyna Nutrition 0.000 title claims abstract description 112
- 235000002313 Crataegus paludosa Nutrition 0.000 title claims abstract description 112
- 235000009840 Crataegus x incaedua Nutrition 0.000 title claims abstract description 112
- 239000003094 microcapsule Substances 0.000 title claims abstract description 77
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 240000000171 Crataegus monogyna Species 0.000 title 1
- 241001092040 Crataegus Species 0.000 claims abstract description 111
- 108010010803 Gelatin Proteins 0.000 claims abstract description 49
- 229920000159 gelatin Polymers 0.000 claims abstract description 49
- 239000008273 gelatin Substances 0.000 claims abstract description 49
- 235000019322 gelatine Nutrition 0.000 claims abstract description 49
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 49
- 108010001441 Phosphopeptides Proteins 0.000 claims abstract description 35
- 239000005018 casein Substances 0.000 claims abstract description 35
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 35
- 235000021240 caseins Nutrition 0.000 claims abstract description 35
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 31
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 30
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 30
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 30
- 239000000463 material Substances 0.000 claims abstract description 20
- 235000007106 Crataegus suborbiculata Nutrition 0.000 claims abstract description 17
- 241000073432 Crataegus suborbiculata Species 0.000 claims abstract description 17
- 235000013202 a hawthorn Nutrition 0.000 claims abstract description 17
- 239000001110 calcium chloride Substances 0.000 claims abstract description 15
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 15
- 239000000284 extract Substances 0.000 claims description 37
- 238000002156 mixing Methods 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000011162 core material Substances 0.000 claims description 16
- 239000000839 emulsion Substances 0.000 claims description 14
- 238000005303 weighing Methods 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 239000003995 emulsifying agent Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 7
- 235000011148 calcium chloride Nutrition 0.000 claims description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- 238000007710 freezing Methods 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 210000004369 blood Anatomy 0.000 abstract description 13
- 239000008280 blood Substances 0.000 abstract description 13
- 238000000926 separation method Methods 0.000 abstract description 7
- 230000009467 reduction Effects 0.000 abstract description 5
- 230000036772 blood pressure Effects 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 34
- 241000700159 Rattus Species 0.000 description 25
- 230000037396 body weight Effects 0.000 description 11
- 230000001603 reducing effect Effects 0.000 description 11
- 210000000056 organ Anatomy 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 229930003935 flavonoid Natural products 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 210000004051 gastric juice Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- -1 flavonoid compounds Chemical class 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 235000020927 12-h fasting Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical group OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/015—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/045—Organic compounds containing nitrogen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/05—Organic compounds containing phosphorus as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供一种山楂黄酮微胶囊及其制备方法和应用,所述芯材包括山楂黄酮提取物,所述壁材包括酪蛋白磷酸肽、氯化钙、明胶和羧甲基纤维素钠。本发明在壁材中加入酪蛋白磷酸肽、明胶和羧甲基纤维素钠与氯化钙固化剂进行配合,提高了山楂黄酮的包埋率和缓释效果,同时还能协同促进山楂黄酮降血压、降血脂等生物活性,提高山楂黄酮的生物利用度。同时,制备山楂黄酮微胶囊的工艺简单,条件温和,制备得到的微胶囊的尺寸较小,分离度高,稳定性好,成本低廉,适用于企业大规模生产。
Description
技术领域
本发明涉及微胶囊制备技术领域,尤其涉及一种山楂黄酮微胶囊及其制备方法和应用。
背景技术
山楂果实中含有丰富的黄酮类化合物,具有抗氧化、降血压、降血脂以及通过抑制炎性生物酶的分泌对伤口起到镇痛愈合的作用等,可以作为功能因子添加到食品或者药品中。但是,黄酮类化合物本身性质并不稳定,易受到空气中氧气、储存环境中光照以及温度等因素的影响,导致黄酮化合物的活性降低甚至活性丧失。采用微胶囊化技术对山楂黄酮进行包埋,不仅有利于黄酮类物质的保存,同时也能使得黄酮类物质在机体中稳定的发挥功能。微胶囊化技术是利用高分子成膜材料将微粒、液滴或气泡等包裹成非均相微小颗粒的一种技术。通过该技术能够达到保护微胶囊芯材理化性质,保持其功能活性并达到可持续释放的目的。但是,目前现有的山楂黄酮微胶囊的制备工艺较复杂,且制备的微胶囊结构不完整,从而导致微胶囊的稳定性较差,进而导致山楂黄酮进入机体后,难以大量到底指定的吸收部位,机体不能对其进行高效的利用,山楂黄酮的生物利用度有待进一步提高。
发明内容
针对现有山楂黄酮微胶囊制备工艺复杂,制备得到的微胶囊结构不完整,以及山楂黄酮生物利用度低的问题,本发明提供一种山楂黄酮微胶囊及其制备方法和应用。
为解决上述技术问题,本发明提供的技术方案是:
一种山楂黄酮微胶囊,包括芯材和壁材,所述芯材包括山楂黄酮提取物,所述壁材包括酪蛋白磷酸肽、氯化钙、明胶和羧甲基纤维素钠。
现有微胶囊一般采用明胶、壳聚糖或海藻酸钠等作为壁材,制备得到的微胶囊的结构不完整,囊壁的强度较小,进入机体后微胶囊的结构很快就会破坏,使得山楂黄酮暴露在机体胃酸、胃蛋白酶等条件下,严重影响山楂黄酮的活性,并导致其难以大量到达指定的吸收部位,从而导致了山楂黄酮口服生物利用度低。本发明在壁材中加入酪蛋白磷酸肽、明胶和羧甲基纤维素钠与氯化钙固化剂进行配合,提高了山楂黄酮的包埋率和缓释效果,同时还能协同促进山楂黄酮降血压、降血脂等生物活性,提高山楂黄酮的生物利用度。
酪蛋白磷酸肽可显著提高钙离子与壁材的结合率,提高微胶囊囊壁结构完整度和强度,同时,酪蛋白磷酸肽结构含有大量的磷酸丝氨酸残基,其在肠道pH弱碱性下环境下可阻止消化酶的进一步作用,提高山楂黄酮微胶囊在人体肠道内的稳定性,提高在肠道的缓释效果。更重要的是,酪蛋白磷酸肽还可以与山楂黄酮相互作用,提高山楂黄酮化合物生物学活性和水溶性,从而提高山楂黄酮的生物利用度,进而充分发挥山楂黄酮降血压、降血脂等功效。
优选的,所述酪蛋白磷酸肽、氯化钙、明胶和羧甲基纤维素钠的质量比为4-6:4-6:75-85:8-12。
与现有技术相比,本发明选用特定比例的酪蛋白磷酸肽、氯化钙、明胶和羧甲基纤维素钠作为微胶囊的壁材,其与氯化钙固化后可形成聚合度高且稳定性好的囊壁,使囊壁具有更好的紧密性和完整性,从而可更好的保护芯材,防止芯材泄漏,从而提高山楂黄酮的生物利用度。
优选的,所述芯材和壁材的质量比为1:6-8。
优选的壁材与芯材的质量比,可使微胶囊具有较好的完整性和缓释性能、可调控释放性能。
优选的,所述山楂黄酮提取物的制备方法为:将含水量为5-15%的山楂冷冻粉碎,过筛,得山楂粉;加入所述山楂粉质量30-40倍的无水乙醇,于50-60℃超声提取30-40min,过滤,得滤渣和滤液;向所述滤渣中加入15-20倍量的无水乙醇,于50-60℃超声提取30-40min,过滤,合并滤液,浓缩,得山楂黄酮提取物。
优选的山楂黄酮的制备方法,可使原料中的山楂黄酮成分更多地溶解到提取液中,且避免了山楂黄酮因高温而遭受破坏,同时也避免了无效物质夹带过多而造成提取产物质量很差的矛盾问题。
本发明还提供一种山楂黄酮微胶囊的制备方法,包括如下步骤:
步骤一、按照设计配比称取各组分,将称取的酪蛋白磷酸肽、氯化钙、明胶和羧甲基纤维素钠分别溶于水中,分别得到酪蛋白磷酸肽溶液、氯化钙溶液、明胶溶液和羧甲基纤维素钠溶液;
步骤二、将称取的山楂黄酮提取物溶于水中,得山楂黄酮溶液;
步骤三、向所述明胶溶液中加入乳化剂,混合均匀,得明胶乳化液,向所述明胶乳化液中加入所述山楂黄酮溶液,混合均匀,加入所述羧甲基纤维素钠溶液,混合均匀,调节pH为4.3-4.7,于0-5℃条件下,加入所述酪蛋白磷酸肽溶液和氯化钙溶液,调节pH为8-9,固化50-70min,离心,冷冻干燥,得所述山楂黄酮微胶囊。
通过上述制备方法得到的微胶囊的粒径集中分布在2μm左右,山楂黄酮的包埋率可达到90%以上。上述制备山楂黄酮微胶囊的工艺简单,条件温和,制备得到的微胶囊的尺寸较小,分离度高,稳定性好,成本低廉,适用于企业大规模生产。
优选的,所述酪蛋白磷酸肽溶液的浓度为15-25mg/mL,所述氯化钙溶液的浓度为15-25mg/mL,所述明胶溶液的浓度为12-18mg/mL,所述羧甲基纤维素钠溶液的浓度为1.2-1.8mg/mL。
优选的各壁材原料的浓度有利于各原料之间的充分混合均匀,提高微胶囊化效率。
优选的,所述山楂黄酮溶液的浓度为35-45mg/mL。
优选的山楂黄酮的浓度有利于山楂黄酮的充分乳化,且提高制备的微胶囊中山楂黄酮的浓度,从而提高微胶囊降血脂的效果。
优选的,所述乳化剂为吐温80。
优选的,所述乳化剂的加入量为所述明胶溶液质量的0.8-1.2%。
优选的乳化剂的用量,可使山楂黄酮充分乳化,达到更优异的包埋效果,有利于形成稳定的微胶囊结构。
本发明还提供上述山楂黄酮微胶囊在降血脂药品或者保健食品中的应用。
本发明制备的山楂黄酮微胶囊具有良好的结构稳定性和强度,可抵抗胃肠道环境对山楂黄酮活性的破坏,具备良好的缓释效果,且包合后能够提高山楂黄酮的活性和溶解度,易于人体吸收,提高山楂黄酮的生物利用度,在降血脂药物或保健食品领域具有广阔的应用前景。
附图说明
图1为本发明实施例1制备的山楂黄酮微胶囊的扫描电镜图片;
图2为本发明实施例1制备的山楂黄酮微胶囊在模拟胃肠液中的缓释效果图。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。
实施例1
一种山楂黄酮微胶囊的制备方法:
步骤一、按照质量比为80:10:5:5称取明胶、羧甲基纤维素钠、酪蛋白磷酸肽和氯化钙,分别将上述各组分溶于水中,分别得到质量浓度为20mg/mL的酪蛋白磷酸肽溶液、质量浓度为20mg/mL的氯化钙溶液、质量浓度为16mg/mL的明胶溶液和质量浓度为1.6mg/mL的羧甲基纤维素钠溶液;
步骤二、按芯材和壁材质量比为1:7,称取山楂黄酮提取物,将称取的山楂黄酮提取物溶于质量浓度为90%的乙醇溶液中,制成浓度为40mg/mL的山楂黄酮溶液;
步骤三、向所述明胶溶液中加入其质量1wt%的吐温80,混合均匀,得明胶乳化液,向所述明胶乳化液中加入所述山楂黄酮溶液,混合均匀,加入所述羧甲基纤维素钠溶液,混合均匀,调节pH为4.5,于0℃条件下,加入所述酪蛋白磷酸肽溶液和氯化钙溶液,调节pH为8.5,固化60min,离心分离,冷冻干燥12h,得所述山楂黄酮微胶囊。
上述山楂黄酮提取物的制备方法为:将含水量为5-15%的山楂冷冻粉碎,过80目筛,得山楂粉;加入所述山楂粉质量35倍的无水乙醇,于55℃超声提取35min,过滤,得滤渣和滤液;向所述滤渣中加入18倍量的无水乙醇,于55℃超声提取35min,过滤,合并滤液,浓缩,得山楂黄酮提取物。
实施例1制备的山楂黄酮微胶囊产品的扫描电镜图片如图1所示,从图中可以看出,通过采用本发明提供的山楂黄酮微胶囊的制备方法可获得形态良好的亚微米级的微胶囊,粒径主要分布在2μm左右,且微胶囊分离度高,成囊效果好。微胶囊的包埋率为91.6%。
实施例2
一种山楂黄酮微胶囊的制备方法:
步骤一、按照质量比为85:12:4:6称取明胶、羧甲基纤维素钠、酪蛋白磷酸肽和氯化钙,分别将上述各组分溶于水中,分别得到质量浓度为15mg/mL的酪蛋白磷酸肽溶液、质量浓度为25mg/mL的氯化钙溶液、质量浓度为12mg/mL的明胶溶液和质量浓度为1.8mg/mL的羧甲基纤维素钠溶液;
步骤二、按芯材和壁材质量比为1:6,称取山楂黄酮提取物,将称取的山楂黄酮提取物溶于质量浓度为80%的乙醇溶液中,制成浓度为35mg/mL的山楂黄酮溶液;
步骤三、向所述明胶溶液中加入其质量0.8wt%的吐温80,混合均匀,得明胶乳化液,向所述明胶乳化液中加入所述山楂黄酮溶液,混合均匀,加入所述羧甲基纤维素钠溶液,混合均匀,调节pH为4.7,于5℃条件下,加入所述酪蛋白磷酸肽溶液和氯化钙溶液,调节pH为8.5,固化60min,离心分离,冷冻干燥12h,得所述山楂黄酮微胶囊。
上述山楂黄酮提取物的制备方法为:将含水量为5-15%的山楂冷冻粉碎,过80目筛,得山楂粉;加入所述山楂粉质量30倍的无水乙醇,于60℃超声提取30min,过滤,得滤渣和滤液;向所述滤渣中加入20倍量的无水乙醇,于60℃超声提取30min,过滤,合并滤液,浓缩,得山楂黄酮提取物。
本实施例制备的山楂黄酮微胶囊的包埋率为90.8%。
实施例3
一种山楂黄酮微胶囊的制备方法:
步骤一、按照质量比为75:8:6:4称取明胶、羧甲基纤维素钠、酪蛋白磷酸肽和氯化钙,分别将上述各组分溶于水中,分别得到质量浓度为25mg/mL的酪蛋白磷酸肽溶液、质量浓度为15mg/mL的氯化钙溶液、质量浓度为18mg/mL的明胶溶液和质量浓度为1.2mg/mL的羧甲基纤维素钠溶液;
步骤二、按芯材和壁材质量比为1:8,称取山楂黄酮提取物,将称取的山楂黄酮提取物溶于质量浓度为70%的乙醇溶液中,制成浓度为45mg/mL的山楂黄酮溶液;
步骤三、向所述明胶溶液中加入其质量1.2wt%的吐温80,混合均匀,得明胶乳化液,向所述明胶乳化液中加入所述山楂黄酮溶液,混合均匀,加入所述羧甲基纤维素钠溶液,混合均匀,调节pH为4.3,于2℃条件下,加入所述酪蛋白磷酸肽溶液和氯化钙溶液,调节pH为8.0,固化70min,离心分离,冷冻干燥12h,得所述山楂黄酮微胶囊。
上述山楂黄酮提取物的制备方法为:将含水量为5-15%的山楂冷冻粉碎,过80目筛,得山楂粉;加入所述山楂粉质量40倍的无水乙醇,于50℃超声提取40min,过滤,得滤渣和滤液;向所述滤渣中加入15倍量的无水乙醇,于50℃超声提取40min,过滤,合并滤液,浓缩,得山楂黄酮提取物。
本实施例制备的山楂黄酮微胶囊的包埋率为91.2%。
对比例1
一种山楂黄酮微胶囊的制备方法:
步骤一、按照质量比为80:10:5称取明胶、羧甲基纤维素钠和氯化钙,分别将上述各组分溶于水中,分别得到质量浓度为20mg/mL的氯化钙溶液、质量浓度为16mg/mL的明胶溶液和质量浓度为1.6mg/mL的羧甲基纤维素钠溶液;
步骤二、按芯材和壁材质量比为1:7,称取山楂黄酮提取物,将称取的山楂黄酮提取物溶于质量浓度为90%的乙醇溶液中,制成浓度为40mg/mL的山楂黄酮溶液;
步骤三、向所述明胶溶液中加入其质量1wt%的吐温80,混合均匀,得明胶乳化液,向所述明胶乳化液中加入所述山楂黄酮溶液,混合均匀,加入所述羧甲基纤维素钠溶液,混合均匀,调节pH为4.5,于0℃条件下,加入所述酪蛋白磷酸肽溶液和氯化钙溶液,调节pH为9.0,固化50min,离心分离,冷冻干燥12h,得所述山楂黄酮微胶囊。
本对比例制备的山楂黄酮微胶囊的包埋率为91.5%。
体外缓释试验
配制模拟胃液和模拟肠液,将实施例1制备的山楂黄酮微胶囊分别置于模拟胃液和模拟肠液中,然后置于37℃的恒温培养箱中进行体外缓释试验,结果如图2所示。
从图中可以看出,在模拟胃液中,山楂黄酮微胶囊的累计释放量经过4h可达到26.09%,此后的4-8h释放速度逐渐减慢,到达8h时累计释放量达到35.91%。在模拟肠液中,山楂黄酮微胶囊经过2h的累计释放量大于其在胃液中的累计释放量,可达到54.61%,从4h开始释放量释放速度减缓,处于较稳定状态。这说明本发明制备的山楂黄酮微胶囊在胃液中较为稳定,当到达主吸收部位小肠后,释放加速,本发明制备的山楂黄酮微胶囊释放规律符合人类营养学消化吸收的特点,在保护和利用山楂黄酮生物活性上具有较好的应用价值。
降血脂功能研究
选取Wistar大鼠63只,随机分为7组,每组9只,分别为空白组,模型组,山楂黄酮提取物组,对比例1组、对比例2组、对比例3组和实施例1组,所有大鼠实验之前饲喂一周以适应环境。按照《保健食品检验与评价技术规范(2003版)》中的方法,在自由采食饲料的同时进行灌胃。
空白组自由采食基础饲料,其余6组自由采食高脂饲料。空白组用蒸馏水灌胃,单次给药剂量为1mL/100g体重;模型组,用蒸馏水灌胃,单次给药剂量为1mL/100g体重;山楂黄酮提取物组,用实施例1提取的山楂黄酮提取物灌胃,单次给药剂量为100mg/Kg体重;对比例1组,用对比例1制备的山楂黄酮微胶囊灌胃,单次给药剂量为50mg/Kg体重;对比例2组,用酪蛋白磷酸肽进行灌胃,单次给药剂量为50mg/Kg体重;对比例3组,实施例1组提取的山楂黄酮提取物和酪蛋白磷酸肽的混合物进行灌胃,山楂黄酮提取物和酪蛋白磷酸肽的质量比与实施例1中相同,单次给药剂量为50mg/Kg体重;实施例1组,用实施例1制备的山楂黄酮微胶囊灌胃,单次给药剂量为50mg/Kg体重;各组大鼠每天给药1次,连续给药5周后,测定大鼠的各项生理生化指标。具体实验设计方案见表1。
其中,高脂饲料的配方为:基础饲料78.8%,猪油10%,蛋黄粉10%,胆固醇1%,胆酸盐0.2%。
表1实验设计方案
在第35天禁食12h后,大鼠股动脉取血,3000r/min离心15min分离出血清,用于血脂指标的测定。解剖大鼠,迅速取出脑、心脏、脾脏及肾脏,剔除其表面的脂肪膜,用生理盐水冲洗干净,用滤纸将水分吸去,然后称重,置洁净塑料盒内密封,血清和各脏器保存于-80℃冰箱,备用。
检测指标:
(1)体重及采食量:每周记录动物体重及采食量。
(2)血清中各生化指标测定:将各组大鼠血清按照每种试剂盒的说明书规范操作,检测以下生化指标:血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)和低密度脂蛋白(LDL-C),并可根据公式计算出动脉硬化指数(AI)值:AI=TC-HDL-C/HDL-C,结果如表2所示。
(3)脏器指数计算
脏器指数(g/100g)=脏器质量×100/大鼠体重,结果如表3所示。
(4)脂肪湿重和脂肪系数:动物取血后,解剖剥离其肾周及生殖器周脂肪组织,称脂肪重量,计算脂肪系数,结果如表4所示。
脂肪系数=脂肪湿重(g)×100%/体重(g)
实验结果:
表2各实验组大鼠血清中各生化指标结果
注:与空白组比较*P<0.05,**P<0.01;与模型组比较#P<0.05,##P<0.01。
由上表可以看出,停药12h后,与空白组比较,模型组的TC、TG、LDL-C均显著性提高(P<0.01),HDL-C显著性降低(P<0.01),说明高脂模型组大鼠造模成功。与模型组相比,黄酮提取物组,对比例1组、对比例3组和实施例1组大鼠的TC、TG均明显降低,且实施例1组TC极显著降低,降低了23%,实施例1组TG含量降低了36.2%。
与模型组(0.45±0.10mmol/l)相比,对比例3组和实施例1组(0.63±0.10mmol/l)HDL-C的含量显著升高(P<0.05),其余组有升高的趋势,但差异不具有统计学意义(P>0.05);对比例3组和实施例1组LDL-C的含量显著降低,其余组有降低的趋势,但差异不具有统计学意义(P>0.05)。而且,对比例3组的各生物指标与黄酮提取物组,以及实施例1组的各生化指标与对比例3组相比,均具有显著差异(P<0.05)。
随着大鼠血脂的改变,各组大鼠的AI均值出现了不同的变化。模型组的AI值高达4.38±1.51,具有较高的动脉粥样硬化风险,通过给药治疗后,对比例1组、实施例1组大鼠的AI值分别下降了30.8%、41.6%。说明实施例1组与对比例1组和对比例3组相比,具有更明显的降低实验大鼠患动脉粥样硬化风险的效果。
表3各实验组大鼠脏器系数结果
组别 | 肝脏系数/% | 脾脏系数/% | 心脏系数/% | 肾脏系数/% |
空白组 | 2.46±0.06<sup>#</sup> | 0.20±0.03<sup>##</sup> | 0.33±0.02 | 0.53±0.04 |
模型组 | 2.70±0.19<sup>*</sup> | 0.24±0.06<sup>**</sup> | 0.32±0.04 | 0.52±0.03 |
黄酮提取物组 | 2.53±0.14 | 0.21±0.01<sup>#</sup> | 0.32±0.04 | 0.51±0.02 |
对比例1组 | 2.63±0.19 | 0.20±0.02<sup>#</sup> | 0.32±0.03 | 0.52±0.03 |
对比例2组 | 2.69±0.20<sup>*</sup> | 0.22±0.08<sup>**</sup> | 0.31±0.05 | 0.54±0.04 |
对比例3组 | 2.48±0.22<sup>#</sup> | 0.20±0.01<sup>#</sup> | 0.31±0.04 | 0.51±0.07 |
实施例1组 | 2.44±0.12<sup>#</sup> | 0.19±0.01<sup>##</sup> | 0.31±0.02 | 0.51±0.04 |
注:与空白组比较*P<0.05,**P<0.01;与模型组比较#P<0.05,##P<0.01。
肝脏和脾脏系数増大,表明喂养高脂饲料会造成大鼠肝损伤和脾损伤。从上表可以看出,与空白组相比,模型组的肝脏系数增加,且具有显著性差异,(P<0.05);与模型组相比,对比例3组和实施例1组肝脏系数具有显著性差异(P<0.05)。
相比于模型组,黄酮提取物组、对比例1组、对比例3组和实施例1组大鼠的脾脏指数明显降低,且与对比例1组、对比例3组和山楂黄酮提取物组相比,实施例1组脾脏指数降低更加显著,降低了20.8%。而且,对比例3组的大鼠脏器系数明显低于黄酮提取物组(P<0.05),实施例1组的大鼠脏器系数明显低于对比例3组(P<0.05)。
表4各实验组脂肪系数结果
注:与空白组比较*P<0.05,**P<0.01;与模型组比较#P<0.05,##P<0.01。
从上表可以看出,与空白组比较,模型组的附睾脂肪系数、肾周脂肪系数和总脂肪系数均有增加,且有统计学意义(P<0.01或P<0.05)。与模型组相比,实施例1组对肾周脂肪系数具有降低作用,且具有极显著性差异(P<0.01),降低了21.3%;黄酮提取物组,对比例1组、对比例3组对肾周脂肪系数也具有降低作用,且具有显著性差异(P<0.05),但是不具有极显著差异。
与模型组相比,各组对附睾脂肪系数均有降低,但是,与对比例1组、对比例3组和黄酮提取物组相比,实施例1组降低效果更明显,下降21.5%。与模型组相比,虽然各组对总脂肪系数均有降低,但只有实施例1组的差异具有统计学意义(P<0.05),仅为3.83%,由此可以说明实施例1组制备的山楂黄酮微胶囊可能有减肥作用。而且,对比例3组的各脂肪系数与黄酮提取物组,以及实施例1组的脂肪系数与对比例3组相比,均具有显著差异(P<0.05)。
通过以上试验证明,酪蛋白磷酸肽的加入不但提高了芯材的包埋率,提高了微胶囊结构的稳定性,同时还与山楂黄酮之间存在协同增效的作用。证明了本发明制备的山楂黄酮微胶囊在降血脂方面具有较好的应用前景。
在本发明限定的其他壁材原料的质量比范围内,及制备方法的工艺参数的其他参数范围内,均可达到与本发明实施例1基本相同的降血脂的效果。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换或改进等,均应包含在本发明的保护范围之内。
Claims (8)
1.一种山楂黄酮微胶囊,包括芯材和壁材,其特征在于,所述芯材包括山楂黄酮提取物,所述壁材包括酪蛋白磷酸肽、氯化钙、明胶和羧甲基纤维素钠;其中,所述酪蛋白磷酸肽、氯化钙、明胶和羧甲基纤维素钠的质量比为4-6:4-6:75-85:8-12;所述芯材和壁材的质量比为1:6-8;
所述山楂黄酮微胶囊是通过如下方法制备得到:
步骤一、按照设计配比称取各组分,将称取的酪蛋白磷酸肽、氯化钙、明胶和羧甲基纤维素钠分别溶于水中,分别得到酪蛋白磷酸肽溶液、氯化钙溶液、明胶溶液和羧甲基纤维素钠溶液;
步骤二、将称取的山楂黄酮提取物溶于质量浓度为70-90%的乙醇溶液中,得山楂黄酮溶液;
步骤三、向所述明胶溶液中加入乳化剂,混合均匀,得明胶乳化液,向所述明胶乳化液中加入所述山楂黄酮溶液,混合均匀,加入所述羧甲基纤维素钠溶液,混合均匀,调节pH为4.3-4.7,于0-5℃条件下,加入所述酪蛋白磷酸肽溶液和氯化钙溶液,调节pH为8-9,固化50-70min,离心,冷冻干燥,得所述山楂黄酮微胶囊。
2.如权利要求1所述的山楂黄酮微胶囊,其特征在于,所述山楂黄酮提取物的制备方法为:将含水量为5-15%的山楂冷冻粉碎,过筛,得山楂粉;加入所述山楂粉质量30-40倍的无水乙醇,于50-60℃超声提取30-40min,过滤,得滤渣和滤液;向所述滤渣中加入15-20倍量的无水乙醇,于50-60℃超声提取30-40min,过滤,合并滤液,浓缩,得山楂黄酮提取物。
3.权利要求1-2任一项所述的山楂黄酮微胶囊的制备方法,其特征在于,包括如下步骤:
步骤一、按照设计配比称取各组分,将称取的酪蛋白磷酸肽、氯化钙、明胶和羧甲基纤维素钠分别溶于水中,分别得到酪蛋白磷酸肽溶液、氯化钙溶液、明胶溶液和羧甲基纤维素钠溶液;
步骤二、将称取的山楂黄酮提取物溶于质量浓度为70-90%的乙醇溶液中,得山楂黄酮溶液;
步骤三、向所述明胶溶液中加入乳化剂,混合均匀,得明胶乳化液,向所述明胶乳化液中加入所述山楂黄酮溶液,混合均匀,加入所述羧甲基纤维素钠溶液,混合均匀,调节pH为4.3-4.7,于0-5℃条件下,加入所述酪蛋白磷酸肽溶液和氯化钙溶液,调节pH为8-9,固化50-70min,离心,冷冻干燥,得所述山楂黄酮微胶囊。
4.如权利要求3所述的山楂黄酮微胶囊的制备方法,其特征在于,步骤一中,所述酪蛋白磷酸肽溶液的浓度为15-25mg/mL,所述氯化钙溶液的浓度为15-25mg/mL,所述明胶溶液的浓度为12-18mg/mL,所述羧甲基纤维素钠溶液的浓度为1.2-1.8mg/mL。
5.如权利要求3所述的山楂黄酮微胶囊的制备方法,其特征在于,所述山楂黄酮溶液的浓度为35-45mg/mL。
6.如权利要求3所述的山楂黄酮微胶囊的制备方法,其特征在于,所述乳化剂为吐温80。
7.如权利要求6所述的山楂黄酮微胶囊的制备方法,其特征在于,所述乳化剂的加入量为所述明胶溶液质量的0.8-1.2%。
8.权利要求1-2任一项所述的山楂黄酮微胶囊在制备降血脂药品或者保健食品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911013909.XA CN110664785B (zh) | 2019-10-23 | 2019-10-23 | 一种山楂黄酮微胶囊及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911013909.XA CN110664785B (zh) | 2019-10-23 | 2019-10-23 | 一种山楂黄酮微胶囊及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110664785A CN110664785A (zh) | 2020-01-10 |
CN110664785B true CN110664785B (zh) | 2022-03-01 |
Family
ID=69083931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911013909.XA Active CN110664785B (zh) | 2019-10-23 | 2019-10-23 | 一种山楂黄酮微胶囊及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110664785B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111568943A (zh) * | 2020-05-22 | 2020-08-25 | 安徽安力肽生物科技有限公司 | 一种葛根黄酮微胶囊的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105166938A (zh) * | 2015-08-11 | 2015-12-23 | 湖南科尔生物技术有限公司 | 一种酪蛋白骨元钙复合益生菌制剂 |
-
2019
- 2019-10-23 CN CN201911013909.XA patent/CN110664785B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105166938A (zh) * | 2015-08-11 | 2015-12-23 | 湖南科尔生物技术有限公司 | 一种酪蛋白骨元钙复合益生菌制剂 |
Non-Patent Citations (6)
Title |
---|
山楂黄酮微胶囊化技术研究;高晗等;《食品科学》;20090815;第86-88页 * |
李彬等.酪蛋白磷酸肽钙一乳清蛋白复合膜物理性质的研究.《食品科学》.2011, * |
红树莓籽黄酮微胶囊工艺优化及其体外模拟胃肠消化;纪秀凤等;《食品工业科技》;20180921;第182-187页 * |
纪秀凤等.红树莓籽黄酮微胶囊工艺优化及其体外模拟胃肠消化.《食品工业科技》.2018, * |
酪蛋白磷酸肽钙一乳清蛋白复合膜物理性质的研究;李彬等;《食品科学》;20110215;第1-5页 * |
高晗等.山楂黄酮微胶囊化技术研究.《食品科学》.2009, * |
Also Published As
Publication number | Publication date |
---|---|
CN110664785A (zh) | 2020-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110559352B (zh) | 一种山楂黄酮微胶囊及其制备方法和应用 | |
RU2315595C2 (ru) | Композиция для энтеросолюбильного покрытия природного продукта, содержащего лектин | |
CN105079281B (zh) | 一种黑果枸杞花色苷粗提物及其缓释微胶囊 | |
CN106667915B (zh) | 一种用于治疗仔猪腹泻的黄芩苷铝干混悬剂 | |
CN111528470A (zh) | 一种刺梨酸钙复合物的制备方法及其产品和应用 | |
CN110664785B (zh) | 一种山楂黄酮微胶囊及其制备方法和应用 | |
CN108524493A (zh) | 二氢杨梅素组合物在抗酒精性肝氧化损伤中的应用 | |
CN105878287B (zh) | 一种美洲大蠊酶解物及其制备方法和应用 | |
CN110368482A (zh) | 一种组合物及其在制备防治心血管疾病药物中的应用 | |
CN114376982B (zh) | 一种壳寡糖肠溶胶囊及其制备方法和应用 | |
CN111184870A (zh) | 一种耐胃液消化型虾青素递送体的制备方法 | |
CN110200926A (zh) | 复合活性冻干粉及其制备方法和应用 | |
KR101143363B1 (ko) | 키토산을 이용한 병풀의 면역 증진용 성분의 식용 나노입자 및 그 제조방법, 그 나노입자를 함유한 식품 | |
CN108576779A (zh) | 魔芋葡甘聚糖-脂质体复合纳米食品递送系统及其制备方法和应用 | |
JP3522186B2 (ja) | プロポリス製剤及びその製造方法 | |
WO2019100843A1 (zh) | 一种浒苔多糖复合降血脂保健品及其制备方法 | |
CN110643655B (zh) | 一种山楂黄酮螯合糖及其制备方法和应用 | |
CN110558556A (zh) | 一种王浆酸微胶囊的制备方法 | |
CN116268401B (zh) | 一种原花青素微胶囊及其制备方法 | |
RU2259835C2 (ru) | Способ получения противовоспалительного, ранозаживляющего, капилляроукрепляющего и иммуномодулирующего средства | |
CN107821605A (zh) | 一种带鱼蛋白肽营养奶粉及其制备方法 | |
CN111568943A (zh) | 一种葛根黄酮微胶囊的制备方法 | |
CN116078297A (zh) | 一种提高蜂胶黄酮消化稳定性的微胶囊包埋技术 | |
CN1280007A (zh) | 木耳调脂胶囊 | |
CN105250919B (zh) | 一种用于预防和/或治疗肝疾病的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |